PMC:7187660 / 504-3058 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":67,"end":75},"obj":"Disease"},{"id":"T4","span":{"begin":168,"end":176},"obj":"Disease"},{"id":"T5","span":{"begin":179,"end":188},"obj":"Disease"},{"id":"T6","span":{"begin":406,"end":414},"obj":"Disease"},{"id":"T7","span":{"begin":704,"end":726},"obj":"Disease"},{"id":"T8","span":{"begin":770,"end":782},"obj":"Disease"},{"id":"T9","span":{"begin":826,"end":834},"obj":"Disease"},{"id":"T10","span":{"begin":878,"end":897},"obj":"Disease"},{"id":"T11","span":{"begin":1048,"end":1056},"obj":"Disease"},{"id":"T12","span":{"begin":1123,"end":1131},"obj":"Disease"},{"id":"T13","span":{"begin":1963,"end":1975},"obj":"Disease"},{"id":"T14","span":{"begin":2044,"end":2052},"obj":"Disease"},{"id":"T15","span":{"begin":2118,"end":2140},"obj":"Disease"},{"id":"T16","span":{"begin":2205,"end":2224},"obj":"Disease"},{"id":"T17","span":{"begin":2287,"end":2293},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p \u003c 0.001) (see Fig. 1b). Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p \u003c 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p \u003c 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p \u003c 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p \u003c 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.\nTable 1 Characteristics between survivors and non-survivors with COVID-19\nCharacteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006\n*Missing data (n = 257 in survivors group)\n#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)\nFig. 1 Fatality rate distribution of age (a) and gender (b). ***p \u003c 0.001"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T4","span":{"begin":109,"end":110},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":236,"end":238},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T6","span":{"begin":566,"end":570},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T7","span":{"begin":566,"end":570},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T8","span":{"begin":618,"end":624},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T9","span":{"begin":1307,"end":1310},"obj":"http://purl.obolibrary.org/obo/CLO_0001414"},{"id":"T10","span":{"begin":1382,"end":1384},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T11","span":{"begin":1812,"end":1816},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T12","span":{"begin":1812,"end":1816},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T13","span":{"begin":1889,"end":1895},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T14","span":{"begin":2225,"end":2228},"obj":"http://purl.obolibrary.org/obo/CLO_0001405"},{"id":"T15","span":{"begin":2414,"end":2417},"obj":"http://purl.obolibrary.org/obo/CLO_0001445"},{"id":"T16","span":{"begin":2523,"end":2524},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T17","span":{"begin":2538,"end":2539},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p \u003c 0.001) (see Fig. 1b). Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p \u003c 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p \u003c 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p \u003c 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p \u003c 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.\nTable 1 Characteristics between survivors and non-survivors with COVID-19\nCharacteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006\n*Missing data (n = 257 in survivors group)\n#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)\nFig. 1 Fatality rate distribution of age (a) and gender (b). ***p \u003c 0.001"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":566,"end":570},"obj":"Chemical"},{"id":"T2","span":{"begin":635,"end":637},"obj":"Chemical"},{"id":"T3","span":{"begin":728,"end":730},"obj":"Chemical"},{"id":"T4","span":{"begin":836,"end":838},"obj":"Chemical"},{"id":"T5","span":{"begin":899,"end":901},"obj":"Chemical"},{"id":"T6","span":{"begin":954,"end":956},"obj":"Chemical"},{"id":"T7","span":{"begin":1228,"end":1230},"obj":"Chemical"},{"id":"T8","span":{"begin":2388,"end":2393},"obj":"Chemical"},{"id":"T9","span":{"begin":2439,"end":2444},"obj":"Chemical"},{"id":"T10","span":{"begin":2474,"end":2479},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p \u003c 0.001) (see Fig. 1b). Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p \u003c 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p \u003c 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p \u003c 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p \u003c 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.\nTable 1 Characteristics between survivors and non-survivors with COVID-19\nCharacteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006\n*Missing data (n = 257 in survivors group)\n#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)\nFig. 1 Fatality rate distribution of age (a) and gender (b). ***p \u003c 0.001"}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":102},"obj":"Sentence"},{"id":"T5","span":{"begin":103,"end":272},"obj":"Sentence"},{"id":"T6","span":{"begin":273,"end":387},"obj":"Sentence"},{"id":"T7","span":{"begin":388,"end":535},"obj":"Sentence"},{"id":"T8","span":{"begin":536,"end":690},"obj":"Sentence"},{"id":"T9","span":{"begin":691,"end":1057},"obj":"Sentence"},{"id":"T10","span":{"begin":1058,"end":1131},"obj":"Sentence"},{"id":"T11","span":{"begin":1132,"end":1240},"obj":"Sentence"},{"id":"T12","span":{"begin":1241,"end":1251},"obj":"Sentence"},{"id":"T13","span":{"begin":1252,"end":1281},"obj":"Sentence"},{"id":"T14","span":{"begin":1282,"end":1321},"obj":"Sentence"},{"id":"T15","span":{"begin":1322,"end":1363},"obj":"Sentence"},{"id":"T16","span":{"begin":1364,"end":1408},"obj":"Sentence"},{"id":"T17","span":{"begin":1409,"end":1453},"obj":"Sentence"},{"id":"T18","span":{"begin":1454,"end":1502},"obj":"Sentence"},{"id":"T19","span":{"begin":1503,"end":1549},"obj":"Sentence"},{"id":"T20","span":{"begin":1550,"end":1594},"obj":"Sentence"},{"id":"T21","span":{"begin":1595,"end":1641},"obj":"Sentence"},{"id":"T22","span":{"begin":1642,"end":1658},"obj":"Sentence"},{"id":"T23","span":{"begin":1659,"end":1707},"obj":"Sentence"},{"id":"T24","span":{"begin":1708,"end":1745},"obj":"Sentence"},{"id":"T25","span":{"begin":1746,"end":1796},"obj":"Sentence"},{"id":"T26","span":{"begin":1797,"end":1810},"obj":"Sentence"},{"id":"T27","span":{"begin":1811,"end":1887},"obj":"Sentence"},{"id":"T28","span":{"begin":1888,"end":1941},"obj":"Sentence"},{"id":"T29","span":{"begin":1942,"end":1961},"obj":"Sentence"},{"id":"T30","span":{"begin":1962,"end":2042},"obj":"Sentence"},{"id":"T31","span":{"begin":2043,"end":2116},"obj":"Sentence"},{"id":"T32","span":{"begin":2117,"end":2203},"obj":"Sentence"},{"id":"T33","span":{"begin":2204,"end":2285},"obj":"Sentence"},{"id":"T34","span":{"begin":2286,"end":2351},"obj":"Sentence"},{"id":"T35","span":{"begin":2352,"end":2394},"obj":"Sentence"},{"id":"T36","span":{"begin":2395,"end":2480},"obj":"Sentence"},{"id":"T37","span":{"begin":2481,"end":2554},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p \u003c 0.001) (see Fig. 1b). Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p \u003c 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p \u003c 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p \u003c 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p \u003c 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.\nTable 1 Characteristics between survivors and non-survivors with COVID-19\nCharacteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006\n*Missing data (n = 257 in survivors group)\n#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)\nFig. 1 Fatality rate distribution of age (a) and gender (b). ***p \u003c 0.001"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":704,"end":726},"obj":"Phenotype"},{"id":"T2","span":{"begin":770,"end":782},"obj":"Phenotype"},{"id":"T3","span":{"begin":1963,"end":1975},"obj":"Phenotype"},{"id":"T4","span":{"begin":2118,"end":2140},"obj":"Phenotype"},{"id":"T5","span":{"begin":2287,"end":2293},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p \u003c 0.001) (see Fig. 1b). Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p \u003c 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p \u003c 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p \u003c 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p \u003c 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.\nTable 1 Characteristics between survivors and non-survivors with COVID-19\nCharacteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006\n*Missing data (n = 257 in survivors group)\n#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)\nFig. 1 Fatality rate distribution of age (a) and gender (b). ***p \u003c 0.001"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T6","span":{"begin":67,"end":75},"obj":"SP_7"},{"id":"T7","span":{"begin":168,"end":178},"obj":"SP_7"},{"id":"T8","span":{"begin":406,"end":414},"obj":"SP_7"},{"id":"T9","span":{"begin":704,"end":718},"obj":"UBERON:0004535"},{"id":"T10","span":{"begin":878,"end":889},"obj":"UBERON:0001004"},{"id":"T11","span":{"begin":1048,"end":1056},"obj":"SP_7"},{"id":"T12","span":{"begin":1123,"end":1153},"obj":"SP_7"},{"id":"T13","span":{"begin":2118,"end":2132},"obj":"UBERON:0004535"},{"id":"T89898","span":{"begin":67,"end":75},"obj":"SP_7"},{"id":"T58247","span":{"begin":168,"end":178},"obj":"SP_7"},{"id":"T56005","span":{"begin":406,"end":414},"obj":"SP_7"},{"id":"T25359","span":{"begin":704,"end":718},"obj":"UBERON:0004535"},{"id":"T45386","span":{"begin":878,"end":889},"obj":"UBERON:0001004"},{"id":"T24778","span":{"begin":1048,"end":1056},"obj":"SP_7"},{"id":"T56769","span":{"begin":1123,"end":1153},"obj":"SP_7"},{"id":"T38161","span":{"begin":2118,"end":2132},"obj":"UBERON:0004535"}],"text":"The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p \u003c 0.001) (see Fig. 1b). Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p \u003c 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p \u003c 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p \u003c 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p \u003c 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.\nTable 1 Characteristics between survivors and non-survivors with COVID-19\nCharacteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006\n*Missing data (n = 257 in survivors group)\n#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)\nFig. 1 Fatality rate distribution of age (a) and gender (b). ***p \u003c 0.001"}

{"project":"LitCovid-PubTator","denotations":[{"id":"17","span":{"begin":1963,"end":1975},"obj":"Disease"},{"id":"18","span":{"begin":2044,"end":2052},"obj":"Disease"},{"id":"19","span":{"begin":2118,"end":2140},"obj":"Disease"},{"id":"20","span":{"begin":2205,"end":2224},"obj":"Disease"},{"id":"21","span":{"begin":2287,"end":2293},"obj":"Disease"},{"id":"23","span":{"begin":1123,"end":1131},"obj":"Disease"},{"id":"41","span":{"begin":127,"end":135},"obj":"Species"},{"id":"42","span":{"begin":202,"end":210},"obj":"Species"},{"id":"43","span":{"begin":340,"end":348},"obj":"Species"},{"id":"44","span":{"begin":423,"end":426},"obj":"Species"},{"id":"45","span":{"begin":431,"end":436},"obj":"Species"},{"id":"46","span":{"begin":571,"end":579},"obj":"Species"},{"id":"47","span":{"begin":625,"end":633},"obj":"Species"},{"id":"48","span":{"begin":1034,"end":1042},"obj":"Species"},{"id":"49","span":{"begin":67,"end":75},"obj":"Disease"},{"id":"50","span":{"begin":168,"end":188},"obj":"Disease"},{"id":"51","span":{"begin":406,"end":414},"obj":"Disease"},{"id":"52","span":{"begin":704,"end":726},"obj":"Disease"},{"id":"53","span":{"begin":770,"end":782},"obj":"Disease"},{"id":"54","span":{"begin":826,"end":834},"obj":"Disease"},{"id":"55","span":{"begin":878,"end":897},"obj":"Disease"},{"id":"56","span":{"begin":945,"end":952},"obj":"Disease"},{"id":"57","span":{"begin":1048,"end":1056},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:D006973"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:D003920"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D002318"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:D012140"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"MESH:D009369"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:C000657245"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:9606"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"Tax:9606"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"Tax:9606"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"Tax:9606"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"Tax:9606"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:9606"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:9606"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:9606"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:C000657245"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:C000657245"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:C000657245"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:D002318"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D006973"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D003920"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:D012140"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D009369"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p \u003c 0.001) (see Fig. 1b). Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p \u003c 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p \u003c 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p \u003c 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p \u003c 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.\nTable 1 Characteristics between survivors and non-survivors with COVID-19\nCharacteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006\n*Missing data (n = 257 in survivors group)\n#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)\nFig. 1 Fatality rate distribution of age (a) and gender (b). ***p \u003c 0.001"}